FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 麗珠醫藥集團股份有限公司 呈交日期： 2025年7月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關 ...

丽珠医药(01513.HK)7月29日耗资276.31万元回购6.59万股A股 丽珠医药(01513.HK)7月28日耗资288.6万 元回购6.9万股A股 格隆汇7月29日丨丽珠医药(01513.HK)发布公告，2025年7月29日耗资276.31万元人民币回购6.59万股A 股，回购价格每股41.63-41.99元。 相关事件 ...

智通财经APP讯，丽珠医药(01513)发布公告，于2025年7月29日该公司斥资人民币276.31万元回购6.59万 股A股，回购价格为每股人民币41.63-41.99元。 该信息由智通财经网提供 ...

丽珠医药(01513)发布公告，于2025年7月29日该公司斥资人民币276.31万元回购6.59万股A股，回购价格 为每股人民币41.63-41.99元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 第 2 頁 共 11 頁 v 1.3.0 公司名稱： 麗珠醫藥集團股份有限公司 呈交日期： 2025年7月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股 ...

Investment Rating - The report rates the mother and baby consumption industry as "Overweight" [2][9] Core Insights - The introduction of a national childcare subsidy of 3,600 yuan per child per year, totaling up to 10,800 yuan per child, is expected to improve consumption expectations in the mother and baby sector [3] - The report highlights that despite a decline in birth rates over the past seven years, the overall mother and baby market has experienced a compound annual growth rate (CAGR) of over 15% from 2018 to 2024 due to consumption upgrades and refined parenting [3] - The report emphasizes the rise of domestic brands in the mother and baby sector, with significant market share gains and a return of industry influence to local brands [3] Summary by Sections National Childcare Subsidy - The national childcare subsidy program will start on January 1, 2025, providing cash subsidies to families with children under three years old, with a basic standard of 3,600 yuan per year [3] - Local governments are expected to introduce additional subsidies, creating a wave of local support for childbirth [3] Market Growth and Opportunities - The mother and baby market is projected to rebound due to improved policies and an anticipated increase in birth rates in 2024 [3] - Key sectors and companies recommended for investment include: - Fertility and reproductive health: Focus on companies like Jinxin Reproductive and Livzon Pharmaceutical [3] - Infant nutrition: Recommendations include China Feihe and Yili Group [3] - Baby appliances: Suggested investment in Bear Electric [3] - Apparel and home textiles: Companies like Semir and Anta are highlighted [3] - Baby care products: Brands such as Runben and New Page are recommended [3] Valuation Table - The report includes a valuation table with various companies in the mother and baby sector, indicating their stock prices, market capitalization, and profit forecasts for 2025, 2026, and 2027, along with corresponding investment ratings [4]

Investment Rating - The industry investment rating is "Overweight (Maintain)" [1] Core Viewpoints - The report highlights that the National Medical Insurance Administration's clarification on not using the lowest price as a reference for centralized procurement is expected to continue promoting and optimizing procurement policies, enhancing the participation of pharmaceutical and medical device companies, and balancing quality and innovation in procurement [7] - LZM012 from Livzon Pharmaceutical has successfully reached its primary research endpoint in Phase III clinical trials, showcasing a dual blockade mechanism that comprehensively inhibits inflammatory responses, providing a new solution for achieving deep clearance of skin lesions and sustained relief [7] Summary by Sections Industry Overview - The report focuses on the pharmaceutical and biotechnology industry, emphasizing the recent developments in centralized procurement and the impact on drug pricing and market dynamics [3][4] Clinical Research Highlights - Livzon Pharmaceutical's LZM012 is the first IL-17A/F dual-target inhibitor to complete Phase III clinical trials in China, demonstrating faster onset and superior efficacy compared to the benchmark drug, Secukinumab [4][6] - Key findings from the clinical trial include: - LZM012 achieved a PASI 75 response rate of 65.7% at week 4, outperforming Secukinumab's 50.3% [4] - At week 12, the PASI 100 response rate for LZM012 was 49.5%, compared to 40.2% for Secukinumab, indicating significant efficacy [4] - Long-term efficacy was sustained, with PASI 100 response rates of 75.9% and 62.6% at week 52 for LZM012 under different dosing regimens, surpassing Secukinumab's 61.6% [4] - Safety profiles were comparable between LZM012 and the control group, with similar rates of adverse events [6] Investment Recommendations - The report suggests focusing on companies such as China National Pharmaceutical Group, Hengrui Medicine, and Livzon Pharmaceutical due to their promising developments and the favorable regulatory environment [7]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 麗珠醫藥集團股份有限公司 呈交日期： 2025年7月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 麗珠醫藥集團股份有限公司 呈交日期： 2025年7月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01513 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件 ...

Group 1 - The core viewpoint of the news is that Kangmand Capital has conducted research on Lijuz Group, highlighting the promising clinical data of its IL-17A/F project (LZM012) for psoriasis, which shows superiority over Secukinumab and rapid onset of action [1] - Lijuz Group plans to develop LZM012 for ankylosing spondylitis and pyoderma gangrenosum, and aims to advance overseas licensing [1] - The company is establishing a small nucleic acid technology platform, starting with a gout project, to build a research and development system and production line [1] - In 2024, Lijuz Group intends to introduce six new drug projects to strengthen its leading position in chronic disease areas and expand its innovative drug pipeline [1] - The small nucleic acid project LZHN2408 and products with global revenue-sharing mechanisms are expected to facilitate overseas licensing [1] - The acquisition of Vietnam's IMP Company aims to establish a presence in the Southeast Asian market, integrate production capabilities, and promote overseas sales [1] - Lijuz Group is enhancing research and development efficiency through strategic research deployment, improved management structure, and strengthened project evaluation and adjustment management [1]